Literature DB >> 19449166

Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders.

S Evans1, K Forester, J M Pettiford, O Morozova.   

Abstract

Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position. Components of spasticity, rigidity, and dystonia may all need to be considered in a comprehensive treatment programme. Complications of disordered tone include skin breakdown, pain, sleep disturbance, and dysphagia. With an integrated approach to use of medications and equipment as well as implementation of therapy and therapeutic exercise, physiatrists can help maximize functional independence for children with this group of disorders. Pharmacological treatment includes GABA-agonists including baclofen and benzodiazepines, alpha-2 adrenergic agonists, L: -dopa and dopaminergic agents, and dantrolene. Intrathecal baclofen may be used in patients refractory to these medications. In addition, physicians may utilize botulinum toxin, phenol, or surgical interventions such as selective dorsal rhizotomy or tendon lengthening. Pharmacological treatment must be used in conjunction with appropriate adaptive equipment in order to maximize therapeutic benefit. Focus on function in an attempt to increase independence is targeted to improve the child's quality of life. We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449166     DOI: 10.1007/s10545-009-1190-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  Pharmacologic management of spasticity in cerebral palsy.

Authors:  James F Mooney; L Andrew Koman; Beth P Smith
Journal:  J Pediatr Orthop       Date:  2003 Sep-Oct       Impact factor: 2.324

Review 2.  Intrathecal baclofen therapy in children.

Authors:  A Leland Albright; Susan S Ferson
Journal:  Neurosurg Focus       Date:  2006-08-15       Impact factor: 4.047

Review 3.  Physical management of spasticity.

Authors:  P Helsel; J McGee; C Graveline
Journal:  J Child Neurol       Date:  2001-01       Impact factor: 1.987

4.  Diagnosis and treatment of neurotransmitter disorders.

Authors:  Phillip L Pearl; Thomas R Hartka; Jacob Taylor
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.598

5.  Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome.

Authors:  D Fehlings; M Rang; J Glazier; C Steele
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

Review 6.  The human stretch reflex and the motor cortex.

Authors:  P B Matthews
Journal:  Trends Neurosci       Date:  1991-03       Impact factor: 13.837

Review 7.  Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion.

Authors:  N H Mayer
Journal:  Muscle Nerve Suppl       Date:  1997

8.  Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population.

Authors:  Kat Kolaski; Samuel J Ajizian; Leah Passmore; Nath Pasutharnchat; L Andrew Koman; Beth P Smith
Journal:  Am J Phys Med Rehabil       Date:  2008-07       Impact factor: 2.159

Review 9.  The pediatric neurotransmitter disorders.

Authors:  Phillip L Pearl; Jacob L Taylor; Stacey Trzcinski; Alex Sokohl
Journal:  J Child Neurol       Date:  2007-05       Impact factor: 1.987

Review 10.  Classification and definition of disorders causing hypertonia in childhood.

Authors:  Terence D Sanger; Mauricio R Delgado; Deborah Gaebler-Spira; Mark Hallett; Jonathan W Mink
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.